{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:54:00Z","timestamp":1765212840074,"version":"3.46.0"},"reference-count":23,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Nemolizumab provides rapid and effective relief from pruritus in patients with atopic dermatitis. However, it is frequently associated with cutaneous adverse events, and reliable predictors of their severity have not yet been clearly identified. This study aimed to investigate the relationship between the severity of nemolizumab-associated cutaneous adverse events and patients\u2019 clinical background and to explore baseline factors that may be useful in predicting their severity. Methods: We retrospectively analyzed data from 40 patients with atopic dermatitis who received nemolizumab between May 2023 and March 2025. Clinical variables included demographics, prior therapies, phenotype, baseline Eczema Area and Severity Index subscores, serum biomarker levels, and treatment courses. The severity of cutaneous adverse events was classified as mild (&lt;10% body surface area or limited to dryness\/desquamation) or moderate-to-severe (\u226510% body surface area). Results: Cutaneous adverse events occurred in 31 of 40 patients (78%); 13 were moderate-to-severe and 18 were mild. Most events appeared within 16 weeks of treatment initiation. Severity was associated with age, duration of disease, serum Thymus and Activation-Regulated Chemokine (TARC) level, and clinical phenotype. Patients with trunk-dominant phenotypes showed more severe cutaneous adverse events than patients with extremity-dominant or prurigo-type atopic dermatitis. Most cutaneous adverse events resolved within 12 weeks using topical therapy, without requiring treatment discontinuation. Conclusions: Baseline characteristics such as age, duration of disease, serum TARC levels, and severity of trunk lesions may be useful in predicting the risk of severe cutaneous adverse events, supporting their potential use in pre-treatment assessment and patient counseling.<\/jats:p>","DOI":"10.3390\/jcm14248657","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:20:29Z","timestamp":1765210829000},"page":"8657","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World, Single-Center Analysis of Cutaneous Adverse Events with Nemolizumab: Toward Safer and More Effective Use"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8550-3536","authenticated-orcid":false,"given":"Akiko","family":"Sugiyama","sequence":"first","affiliation":[{"name":"Department of Allergology, NHO Fukuoka National Hospital, Fukuoka 811-1394, Japan"},{"name":"Department of Dermatology, NHO Fukuoka National Hospital, Fukuoka 811-1394, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2811-8273","authenticated-orcid":false,"given":"Takeshi","family":"Nakahara","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medical Science, Kyushu University, Fukuoka 812-8582, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Kojima","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, NHO Fukuoka National Hospital, Fukuoka 811-1394, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruko","family":"Nishie","sequence":"additional","affiliation":[{"name":"Department of Dermatology, NHO Fukuoka National Hospital, Fukuoka 811-1394, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miku","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Dermatology, NHO Fukuoka National Hospital, Fukuoka 811-1394, Japan"},{"name":"Department of Dermatology, Graduate School of Medical Science, Kyushu University, Fukuoka 812-8582, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Hiramoto","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, NHO Fukuoka National Hospital, Fukuoka 811-1394, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/bjd.14207","article-title":"The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study","volume":"174","author":"Nemoto","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/09546634.2017.1290205","article-title":"Interleukin-31 pathway and its role in atopic dermatitis: A systematic review","volume":"28","author":"Saleem","year":"2017","journal-title":"J. Dermatol. Treat."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1917006","article-title":"Trial of nemolizumab and topical agents for atopic dermatitis with pruritus","volume":"383","author":"Kabashima","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/bjd\/ljae131","article-title":"Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: Results from a randomized double-blind placebo-controlled phase II\/III clinical study in patients aged \u226513 years","volume":"191","author":"Yokozeki","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjd.20873","article-title":"Nemolizumab plus topical agents in patients with atopic dermatitis and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: Results from two phase III, long-term studies","volume":"186","author":"Kabashima","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2177096","DOI":"10.1080\/09546634.2023.2177096","article-title":"Clinically meaningful improvements in cutaneous lesions and quality of life in patients with atopic dermatitis with greater pruritus reductions after treatment with 60 mg nemolizumab: Subgroup analysis from a phase 3 randomized controlled trial","volume":"34","author":"Kabashima","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/bjd\/ljad268","article-title":"Efficacy and safety of nemolizumab in paediatric patients aged 6\u201312 years with atopic dermatitis with moderate-to-severe pruritus: Results from a phase III randomized double-blind placebo-controlled multicentre study","volume":"190","author":"Igarashi","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/bjd\/ljae458","article-title":"Long-term (68 weeks) administration of nemolizumab in paediatric patients aged 6\u201312 years with atopic dermatitis with moderate-to-severe pruritus: Efficacy and safety data from a phase III study","volume":"192","author":"Igarashi","year":"2025","journal-title":"Br. J. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1684\/ejd.2023.4551","article-title":"Real-world effectiveness and safety of nemolizumab for atopic dermatitis in Japanese patients: A single-centre retrospective study","volume":"33","author":"Miyawaki","year":"2023","journal-title":"Eur. J. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"100457","DOI":"10.1016\/j.jacig.2025.100457","article-title":"Clinical factors predicting nemolizumab response in atopic dermatitis","volume":"4","author":"Masuo","year":"2025","journal-title":"J. Allergy Clin. Immunol. Glob."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/jdv.17218","article-title":"Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: Subpopulation (EASI \u2265 16) analysis of a randomized phase 2B study","volume":"35","author":"Silverberg","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Mima, Y., Yamamoto, M., and Iozumi, K. (2025). Cutaneous adverse events following nemolizumab administration: A review. J. Clin. Med., 14.","DOI":"10.3390\/jcm14093026"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e316","DOI":"10.1111\/1346-8138.17589","article-title":"Nemolizumab-induced exacerbation of atopic dermatitis","volume":"52","author":"Kamada","year":"2025","journal-title":"J. Dermatol."},{"key":"ref_15","first-page":"e79070","article-title":"A case of erythema multiforme following the administration of nemolizumab","volume":"17","author":"Mima","year":"2025","journal-title":"Cureus"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/1346-8138.17626","article-title":"Characteristics of suitable cases for nemolizumab based on clinical findings and cutaneous adverse events","volume":"52","author":"Sugiyama","year":"2025","journal-title":"J. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transpl."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"eabi6887","DOI":"10.1126\/sciimmunol.abi6887","article-title":"IL-31-dependent neurogenic inflammation restrains cutaneous type 2 immune response in allergic dermatitis","volume":"8","author":"Fassett","year":"2023","journal-title":"Sci. Immunol."},{"key":"ref_19","first-page":"223","article-title":"Th1\/Th2 balance: The hypothesis, its limitations, and implications for health and disease","volume":"8","author":"Kidd","year":"2003","journal-title":"Altern. Med. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000323299","article-title":"The role of cytokines\/chemokines in the pathogenesis of atopic dermatitis","volume":"41","author":"Yamanaka","year":"2011","journal-title":"Curr. Probl. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaci.2013.10.048","article-title":"A sensory neuron-expressed IL-31 receptor mediates T-helper-cell-dependent itch: Involvement of TRPV1 and TRPA1","volume":"133","author":"Cevikbas","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12264-017-0200-8","article-title":"Regulation of pain and itch by TRP channels","volume":"34","author":"Moore","year":"2018","journal-title":"Neurosci. Bull."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Miyauchi, K., Ki, S., Ukai, M., Suzuki, Y., Inoue, K., Suda, W., Matsui, T., Ito, Y., Honda, K., and Koseki, H. (2021). Essential role of STAT3 signaling in hair follicle homeostasis. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.663177"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/24\/8657\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:49:24Z","timestamp":1765212564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/24\/8657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,6]]},"references-count":23,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["jcm14248657"],"URL":"https:\/\/doi.org\/10.3390\/jcm14248657","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,6]]}}}